BioSpace News Archive

KORU Medical Systems to Participate in Canaccord Genuity’s 41 st Annual Growth Conference

Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today the initiation of a Named Patient Program for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg globally for the treatment of diabetic macular edema (DME) and in Europe and the Middle East, for the treatment of non-infectious posterior uveitis (NIU-PS).

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2021.

AltruBio Inc., a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, announced the appointment of Jeroen Grasman as chief financial officer.

Krystal Biotech Inc., the leader in redosable gene therapies for rare diseases, reported financial results and key operational progress updates for the second quarter ending June 30, 2021.

Pacific Biosciences of California, Inc. announced that its executives will be speaking at the following investor conference:.

R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today introduced R1 Entri™, an intelligent patient engagement solution, at booth #4721 at the HIMSS21 Global Health Conference & Exhibition in Las Vegas.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the company’s New Drug Application (NDA) for DARE-BV1 for the treatment of bacterial vaginosis.

PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that Executive Vice President and Chief Financial Officer Dikla Czaczkes Akselbrad will present a corporate overview at the Investor Summit Virtual Conference being held August 17 – 18, 2021.

IceCure Medical Ltd., developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, yesterday announced that it has implemented an 8-for-1 reverse split of its ordinary shares effective prior to the opening of market trading on Sunday, August 8, 2021.